Christopher A. Klebanoff, M.D.
Christopher A. Klebanoff, M.D.
Assistant Clinical Investigator

Dr. Klebanoff's lab is interested in cellular differentiation and maturation of components of both the innate and adoptive immune systems, with a specific emphasis on how controlling immunologic differentiation can impact adoptive T cell immunotherapies. The lab's overall goal is to develop promising new immunotherapies for the treatment of human cancers built upon a mechanism-based understanding of CD8+ T cell and conventional dendritic cell differentiation and functions discovered in our laboratory.

Areas of Expertise
1) immunotherapy 2) adoptive T cell therapy 3) CD8+ T cell subsets 4) T cell memory 5) IL-15 6) metastatic melanoma

Contact Info

Christopher A. Klebanoff, M.D.
Center for Cancer Research
National Cancer Institute
Building 10/CRC, Room 3W-5816
Bethesda, MD 20892
301-451-6912
klebanoc@mail.nih.gov

Our lab is interested in cellular differentiation and maturation of components of both the innate and adoptive immune systems, with a specific emphasis on how controlling immunologic differentiation can impact adoptive T cell immunotherapies. Our overall goal is to develop promising new immunotherapies for the treatment of cancer built upon a mechanism-based understanding of CD8+ T cell and conventional dendritic cell functions discovered in our laboratory.

Scientific Focus Areas:
Clinical Research, Immunology, Stem Cell Biology

View Dr. Klebanoff's PubMed Summary.

Selected Recent Publications
  1. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.
    Nature. 498: 506-10, 2013. [ Journal Article ]
  2. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.
    J. Clin. Invest. 123: 4479-88, 2013. [ Journal Article ]
  3. Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.
    Blood. 122: 2125-34, 2013. [ Journal Article ]
  4. Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.
    J. Exp. Med. 210: 1961-76, 2013. [ Journal Article ]
  5. Gattinoni L, Klebanoff CA, Restifo NP.
    Nat. Rev. Cancer. 12: 671-84, 2012. [ Journal Article ]

Christopher A. Klebanoff initially came to the National Cancer Institute as a Howard Hughes Medical Institute-National Institutes of Health Research Scholar in 2002. After graduating with honors from Emory University School of Medicine, he served as an Osler House Officer in the Department of Medicine at the Johns Hopkins Hospital on a physician-scientist pathway. He completed post-doctoral and clinical fellowship training in Medical Oncology and Immunotherapy at the National Cancer Institute, serving as a Chief Medical Oncology Fellow in 2008-2009.

Name Position
Tori Yamamoto Special Volunteer

Research

Our lab is interested in cellular differentiation and maturation of components of both the innate and adoptive immune systems, with a specific emphasis on how controlling immunologic differentiation can impact adoptive T cell immunotherapies. Our overall goal is to develop promising new immunotherapies for the treatment of cancer built upon a mechanism-based understanding of CD8+ T cell and conventional dendritic cell functions discovered in our laboratory.

Scientific Focus Areas:
Clinical Research, Immunology, Stem Cell Biology

Publications

View Dr. Klebanoff's PubMed Summary.

Selected Recent Publications
  1. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, Sciumè G, Zare H, Vahedi G, Dema B, Yu Z, Liu H, Takahashi H, Rao M, Muranski P, Crompton JG, Punkosdy G, Bedognetti D, Wang E, Hoffmann V, Rivera J, Marincola FM, Nakamura A, Sartorelli V, Kanno Y, Gattinoni L, Muto A, Igarashi K, O'Shea JJ, Restifo NP.
    Nature. 498: 506-10, 2013. [ Journal Article ]
  2. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, Roychoudhuri R, Palmer DC, Muranski P, Karoly ED, Mohney RP, Klebanoff CA, Lal A, Finkel T, Restifo NP, Gattinoni L.
    J. Clin. Invest. 123: 4479-88, 2013. [ Journal Article ]
  3. Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.
    Blood. 122: 2125-34, 2013. [ Journal Article ]
  4. Klebanoff CA, Spencer SP, Torabi-Parizi P, Grainger JR, Roychoudhuri R, Ji Y, Sukumar M, Muranski P, Scott CD, Hall JA, Ferreyra GA, Leonardi AJ, Borman ZA, Wang J, Palmer DC, Wilhelm C, Cai R, Sun J, Napoli JL, Danner RL, Gattinoni L, Belkaid Y, Restifo NP.
    J. Exp. Med. 210: 1961-76, 2013. [ Journal Article ]
  5. Gattinoni L, Klebanoff CA, Restifo NP.
    Nat. Rev. Cancer. 12: 671-84, 2012. [ Journal Article ]

Biography

Christopher A. Klebanoff initially came to the National Cancer Institute as a Howard Hughes Medical Institute-National Institutes of Health Research Scholar in 2002. After graduating with honors from Emory University School of Medicine, he served as an Osler House Officer in the Department of Medicine at the Johns Hopkins Hospital on a physician-scientist pathway. He completed post-doctoral and clinical fellowship training in Medical Oncology and Immunotherapy at the National Cancer Institute, serving as a Chief Medical Oncology Fellow in 2008-2009.

Team

Name Position
Tori Yamamoto Special Volunteer